AstraZeneca Joins Price Cap Movement for Inhalers Following Boehringer Investigation

- AstraZeneca, along with Boehringer Ingelheim and GlaxoSmithKline (GSK), caps out-of-pocket inhaler costs at $35 per month for their respective products in the United States.
- These actions follow a Congressional investigation led by Senator Baldwin and supported by Senator Sanders, focusing on the high prices of inhalers for asthma and chronic obstructive pulmonary disease (COPD).
- AstraZeneca's initiative aligns with Boehringer Ingelheim's earlier announcement and takes effect starting June 1, 2024.
- GSK's price cap will commence on January 1, 2025.
- The move aims to increase accessibility and affordability for millions of Americans relying on inhalers.
- The Senate investigation highlighted significant price disparities between the U.S. market and other countries, such as Britain.
- The Asthma and Allergy Foundation of America welcomed these efforts but called for broader industry collaboration to reduce costs further.